Get startedLog in
    Picture of Genmab A/S logo

    GMAB — Genmab A/S News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

    Picture of Genmab A/S logoGenmab A/S
    13/06/2026 17:46
    BRIEF-Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma 
    June 13 (Reuters) - Genmab A/S GMAB.CO:
    • GENMAB ANNOUNCES EPCORITAMAB MONOTHERAPY AND EPCORITAMAB-BASED COMBINATION REGIMENS DEMONSTRATE HIGH RESPONSE RATES IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Source text: ID:nBw5F1m7ca
    Further company coverage: GMAB.CO

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Genmab A/S

    See all news